Future human clinical trials are needed to validate the translational effects of these pathways in NAFLD treatment, particularly regarding the clinical safety and efficacy of TFEB activators or AMPK/mTOR modulators. This evidence concerns the gene MTOR and metabolic dysfunction-associated steatotic liver disease.